| __timestamp | Intra-Cellular Therapies, Inc. | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 79383000 |
| Thursday, January 1, 2015 | 18187286 | 108402000 |
| Friday, January 1, 2016 | 24758063 | 46928000 |
| Sunday, January 1, 2017 | 23666957 | 74959000 |
| Monday, January 1, 2018 | 30099855 | 79716000 |
| Tuesday, January 1, 2019 | 64947625 | 74669000 |
| Wednesday, January 1, 2020 | 186363444 | 59040000 |
| Friday, January 1, 2021 | 272611040 | 77417000 |
| Saturday, January 1, 2022 | 358782000 | 91473000 |
| Sunday, January 1, 2023 | 409864000 | 94314000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, Intra-Cellular Therapies, Inc. and MannKind Corporation have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Intra-Cellular Therapies saw a staggering increase of nearly 3,900% in SG&A expenses, peaking in 2023. This reflects their aggressive expansion and investment in operational capabilities. In contrast, MannKind Corporation maintained a more stable SG&A expenditure, with a modest 19% increase over the same period. This stability suggests a more conservative approach to operational spending. The data highlights the strategic differences between these two companies, offering insights into their financial priorities and market strategies. As the biotech sector continues to grow, understanding these operational cost trends is crucial for investors and industry analysts alike.
Breaking Down SG&A Expenses: Johnson & Johnson vs Intra-Cellular Therapies, Inc.
Merck & Co., Inc. vs MannKind Corporation: SG&A Expense Trends
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Intra-Cellular Therapies, Inc. Trends and Insights
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. and Dr. Reddy's Laboratories Limited: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Catalent, Inc.
Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Catalent, Inc. and MannKind Corporation
Jazz Pharmaceuticals plc or MannKind Corporation: Who Manages SG&A Costs Better?
HUTCHMED (China) Limited and MannKind Corporation: SG&A Spending Patterns Compared